Clinical Evaluation of Subcutaneous Testosterone Implants in Men With Symptomatic Hypogonadism

Trial statusNot yet recruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexMale
Age18+
SponsorUniversity of Sao Paulo

About this trial

Introduction:

Male hypogonadism is a clinical syndrome associated with significant consequences for health and quality of life. In Brazil, approved testosterone replacement therapy options are limited to injectable formulations and transdermal gels, which are often associated with suboptimal adherence. Subcutaneous testosterone implants, already used in the United States and recommended by international guidelines, represent a promising alternative but are not yet available in Brazil.

Objective:

To evaluate the efficacy, safety, pharmacokinetics, and quality-of-life impact of 200 mg testosterone implants manufactured in Brazil for the treatment of men with symptomatic hypogonadism.

Methods:

This is a prospective interventional study conducted at the Division of Urology of the Hospital das Clínicas, University of São Paulo School of Medicine (FMUSP). Thirty cisgender hypogonadal men meeting strict inclusion and exclusion criteria will be enrolled. Participants will receive subcutaneous testosterone implants totaling 800 mg and will be followed for six months. Serial blood sampling will be performed to assess hormonal levels (total and free testosterone, LH, FSH, and PSA) and metabolic parameters (lipid profile, body mass index, and waist circumference). Validated questionnaires, including the IIEF-15, ADAM, and WHOQOL-BREF, will be used to evaluate sexual function, hypogonadal symptoms, quality of life, and patient satisfaction.

Outcomes:

The primary outcome is the ability of the implants to achieve and maintain therapeutic serum testosterone levels (450-800 ng/dL). Secondary outcomes include pharmacokinetic profile (Cmax, half-life, and mean duration), metabolic effects, changes in quality of life, and treatment adherence.

Clinical Significance:

This study advances the understanding of a testosterone replacement modality that may offer greater convenience for selected patients and for which data on nationally manufactured products are currently lacking. Over a six-month period, the study will investigate laboratory behavior, clinical impact, and patient satisfaction.

Relevance and Impact:

This is the first study of its kind conducted in Brazil, combining methodological rigor with a robust design to evaluate the safety and efficacy of domestically manufactured testosterone implants. The methodology incorporates detailed ethical and scientific criteria, ensuring high-quality data. The results may support regulatory and clinical decision-making, benefiting patients and potentially contributing to the Brazilian Unified Health System (SUS).

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Absence of desire for future fertility.

Two fasting total testosterone measurements ≤ 350 ng/dL obtained between 6:00 and 10:00 a.m.

A positive ADAM questionnaire result (Participants with a prior diagnosis of testosterone deficiency established at this institution who are currently receiving testosterone replacement therapy and wish to participate in the study will be eligible for inclusion after completion of an appropriate washout period of the testosterone formulation in use.)

Disqualifiers

Inability to complete or respond to study questionnaires.

Body mass index (BMI) > 35 kg/m².

Untreated depression, defined as a Beck Depression Inventory score > 20.

Personal history of cancer.

Trial design

Design model

Single group

Treatments tested in this trial

  • Subcutaneous Testosterone Implants

    Drug

    Subcutaneous Testosterone Implants in Men With Symptomatic Hypogonadism

Treatment groups

30 Participants
are divided into 1 treatment group
Group A: Subcutaneous Testosterone ImplantsExperimental treatment 1 intervention

Trial outcomes

Primary outcomes

1

Testosterone 200mg implants in hypogonadal men pharmacokinetics

To evaluate the efficacy of a resorbable subcutaneous testosterone implant (200 mg), administered at a total dose of 800 mg (four 200-mg implants), in achieving and maintaining total serum testosterone concentration between 450 and 800 ng/dL in symptomatic hypogonadal men over a 180-day period

Time frame
180 days

Secondary outcomes

1

Maximum Plasma Testosterone Concentration

Assessment of the maximum plasma concentration of total testosterone.

Time frame
Up to 180 days
2

Time to Maximum Plasma Testosterone Concentration (Tmax)

Assessment of the time required to reach the maximum plasma concentration of total testosterone after implantation.

Time frame
Up to 180 days
3

Plasma Testosterone Elimination Half-Life (T½)

Assessment of the elimination half-life of total testosterone in plasma following implantation.

Time frame
Up to 180 days
4

Average Plasma Testosterone Concentration (Cavg)

Assessment of the average plasma concentration of total testosterone following implantation.

Time frame
Up to 180 days

Other outcomes

Locations

This trial has no locations.

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

This trial is not recruiting at the moment. You can still explore other options: